Close
Close

Regeneron Pharmaceuticals - Cutaneous Squamous Cell Carcinoma

Partner

Not provided

Rare Disease

Cutaneous Squamous Cell Carcinoma

Sponsor

Regeneron Pharmaceuticals

Access Program Information

The objective of this program is to provide access to cemiplimab (REGN2810) to patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for surgery prior to cemiplimab (REGN2810) being commercially available.

Contact

Contact: Clinical Trials Administrator (877-768-4303)

Locations

Free Newsletter